GCC pharma market access

We know the way in.

Market access strategy for pharmaceutical companies in Saudi Arabia and the Gulf — where to sell, at what price, through which channels, and on what timeline. Built on years inside the region's market, not observed from outside it.

What we do

Four questions. One outcome: your product selling in the Gulf.

Every engagement answers the questions a commercial team actually faces — grounded in how Gulf payers, procurement bodies, and institutions decide.

01 / WHERE

Market opportunity & entry

Which Gulf markets are worth entering, in what order, and through which channel — institutional, tender, or private.

  • Market and channel opportunity assessment
  • Entry model evaluation: agent, distributor, or direct
  • Country-by-country entry roadmap
02 / HOW MUCH

Pricing & reimbursement

What your product can realistically sell for — modeled against Gulf reference pricing rules, regional benchmarks, and payer expectations before you commit.

  • Price corridor modeling and reference pricing simulation
  • Launch sequencing to protect regional price levels
  • Price submission and negotiation support
03 / WHEN & HOW LONG

Tender & procurement strategy

When the buying windows open, how long contracts run, and how to position bids — for NUPCO in Saudi Arabia and central procurement across the Gulf.

  • Tender calendars, cycles, and contract-period mapping
  • Bid positioning and pricing corridors from award history
  • Institutional and formulary access strategy
04 / HOW

Launch & access planning

The sequenced commercial plan that ties it together — timeline, volumes, investment view, and the institutional dynamics written guidance doesn't capture.

  • Integrated access roadmap across markets and channels
  • Revenue and volume scenario planning by segment
  • Registration timeline coordination with your regulatory partners
How we work

A defined route, not an open-ended retainer.

Phase 1 — Map

Diagnose the opportunity

We assess your product and target markets against real commercial conditions — and tell you plainly what the route looks like, including where it's blocked or not worth the investment.

Phase 2 — Plan

Build the access strategy

A sequenced plan across markets, price, and procurement timing — with decision points, contract periods, and the institutional dynamics that reports don't capture.

Phase 3 — Move

Execute alongside you

Ongoing advisory through launch, price negotiation, and tender cycles — or focused expert input at the moments that decide the outcome.

Where we work

The Gulf, from the inside.

Our work is anchored in Saudi Arabia — the region's largest pharmaceutical market — with active coverage across the GCC's key institutional buyers.

  • Saudi ArabiaNUPCO · institutional accounts
  • United Arab EmiratesFederal & emirate channels
  • KuwaitMOH central procurement
  • BahrainGovernment & private channels
4
GCC markets covered
15+
Years in-market, inside the region's institutions
3
Therapeutic areas of depth: oncology, transplant, critical care
EN / AR
Working fluently in both languages, both systems
Insights

How access actually works here.

Short, specific briefings on Gulf market access mechanics — written for BD and commercial teams evaluating the region.

Start here

Planning a Gulf market entry?

Tell us about your product and target markets. We'll respond within two business days with an honest read on the opportunity.

Start the conversation